Faricimab treatment outcomes with extended dosing and potential for Q20W intervals in DME: post hoc analysis of the 96-week phase 3 YOSEMITE/RHINE trials
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- June 2024
has subject area
- 06 Biological Sciences (FoR)
- 11 Medical and Health Sciences (FoR)
- Ophthalmology & Optometry (Science Metrix)